Physician profile
David Byron
NPI 1831400597
$1,377.04
in general payments reported to CMS, 2019-2025
23 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.25 · 2020: $20.74 · 2021: $131 · 2022: $46.36 · 2023: $133 · 2024: $622 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $197.57 | 2023-2024 | Grafix Pl, Stravix, Collagenase Santyl |
| Lilly USA, LLC | $176.00 | 2024-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.01 | 2023-2025 | Xifaxan, Trulance |
| Galderma Laboratories, L.P. | $113.49 | 2021 | |
| Averitas Pharma INC. | $110.86 | 2024-2025 | Qutenza |
| Abbvie INC. | $86.00 | 2023-2025 | Vraylar |
| Novo Nordisk INC | $79.96 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $71.16 | 2024-2025 | Airsupra |
| Insulet Corporation | $69.62 | 2024-2025 | Omnipod |
| Inari Medical, INC. | $46.36 | 2022 | |
| Amgen INC. | $34.55 | 2025 | Repatha, Otezla |
| Musculoskeletal Transplant Foundation INC. | $32.24 | 2023 | |
| Vapotherm INC | $26.25 | 2019 | |
| Exact Sciences Corporation | $23.20 | 2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $22.39 | 2024 | Gemtesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $21.05 | 2025 | Veozah |
| Janssen Pharmaceuticals, INC | $20.74 | 2020 | |
| Boston Scientific Corporation | $20.03 | 2024 | Varithena Administration Pack |
| Corcept Therapeutics | $17.31 | 2024 | Korlym |
| Aimmune Therapeutics, INC. | $17.30 | 2024 | |
| Allergan, INC. | $17.16 | 2021 | |
| Abbott Laboratories | $16.87 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $13.92 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Byron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.